Alembic's ANDA215230 for Brimonidine Tartrate and Timolol Maleate Receives AP Status
The FDA has granted an Abbreviated New Drug Application (ANDA) approval status of AP for Alembic's formulation of Brimonidine Tartrate and Timolol Maleate.
Company
Pharmaceutical intelligence for Alembic Pharmaceuticals with 8 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.